These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Cinacalcet for managing secondary hyperparathyroidism in dialysis patients in clinical practice in Belgium: a 16-month observational study (ECHO-B). Debelle F; Meeus G; Dratwa M; Maes B; Vanholder R; Albert A; Schutyser E; Jadoul M Acta Clin Belg; 2013; 68(4):275-81. PubMed ID: 24455797 [TBL] [Abstract][Full Text] [Related]
23. Pharmacodynamics of cinacalcet over 48 hours in patients with controlled secondary hyperparathyroidism: useful data in clinical practice. Arenas MD; de la Fuente V; Delgado P; Gil MT; Gutiérrez P; Ribero J; Rodríguez M; Almadén Y J Clin Endocrinol Metab; 2013 Apr; 98(4):1718-25. PubMed ID: 23463658 [TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and pharmacodynamics of cinacalcet in patients with renal failure receiving hemodialysis and hemodiafiltration therapy . Shi W; Tan X; Li Z; Zhang M; Huang B; Lu F; Jia J; Chen J; Zhong M Int J Clin Pharmacol Ther; 2019 Jun; 57(6):284-289. PubMed ID: 30935461 [TBL] [Abstract][Full Text] [Related]
25. Impact of cinacalcet hydrochloride on bone histology in patients with secondary hyperparathyroidism. Yajima A; Akizawa T; Tsukamoto Y; Kurihara S; Ito A; Ther Apher Dial; 2008 Oct; 12 Suppl 1():S38-43. PubMed ID: 19032526 [TBL] [Abstract][Full Text] [Related]
26. Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Fukagawa M; Yumita S; Akizawa T; Uchida E; Tsukamoto Y; Iwasaki M; Koshikawa S; Nephrol Dial Transplant; 2008 Jan; 23(1):328-35. PubMed ID: 17717030 [TBL] [Abstract][Full Text] [Related]
27. EARLIER: an observational study to evaluate the use of cinacalcet in incident hemodialysis patients with secondary hyperparathyroidism in daily clinical practice. Hemetsberger M; Oberbauer R; Erb H; Pronai W Wien Med Wochenschr; 2015 Oct; 165(19-20):410-8. PubMed ID: 26302869 [TBL] [Abstract][Full Text] [Related]
28. Two Years of Cinacalcet Hydrochloride Treatment Decreased Parathyroid Gland Volume and Serum Parathyroid Hormone Level in Hemodialysis Patients With Advanced Secondary Hyperparathyroidism. Yamada S; Tokumoto M; Taniguchi M; Toyonaga J; Suehiro T; Eriguchi R; Fujimi S; Ooboshi H; Kitazono T; Tsuruya K Ther Apher Dial; 2015 Aug; 19(4):367-77. PubMed ID: 25851690 [TBL] [Abstract][Full Text] [Related]
29. Impact of cinacalcet pre-transplantation on mineral metabolism in renal transplant recipients. Sharma AK; Masterson R; Holt SG; Tan SJ; Hughes PD; Chu M; Jayadeva P; Toussaint ND Nephrology (Carlton); 2016 Jan; 21(1):46-54. PubMed ID: 26072678 [TBL] [Abstract][Full Text] [Related]
30. Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients. Shireman TI; Almehmi A; Wetmore JB; Lu J; Pregenzer M; Quarles LD Am J Kidney Dis; 2010 Dec; 56(6):1108-16. PubMed ID: 20951487 [TBL] [Abstract][Full Text] [Related]
31. [Retrospective assessment of effective and safety of cinacalcet for the treatment of secondary hyperparathyroidism depending on basal iPTH level]. Mercadal Orfila G; Blasco Mascaró I Farm Hosp; 2012; 36(1):11-5. PubMed ID: 21514862 [TBL] [Abstract][Full Text] [Related]
32. Safety and efficiency of treatment with cinacalcet of haemodialysed patients with chronic kidney disease and secondary hyperparathyroidism. Kuczera P; Adamczak M; Więcek A Endokrynol Pol; 2013; 64(3):176-81. PubMed ID: 23873419 [TBL] [Abstract][Full Text] [Related]
33. Effect of cinacalcet cessation on hyperparathyroidism in kidney transcaplant patients after long-term dialysis therapy. Nakai K; Fujii H; Yoshikawa M; Kono K; Yonekura Y; Goto S; Ishimura T; Takeda M; Fujisawa M; Nishi S Clin Exp Nephrol; 2015 Dec; 19(6):1184-8. PubMed ID: 25782729 [TBL] [Abstract][Full Text] [Related]
34. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism. Sprague SM; Wetmore JB; Gurevich K; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K Clin J Am Soc Nephrol; 2015 Jun; 10(6):1021-30. PubMed ID: 25873267 [TBL] [Abstract][Full Text] [Related]
36. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. Nemeth EF; Heaton WH; Miller M; Fox J; Balandrin MF; Van Wagenen BC; Colloton M; Karbon W; Scherrer J; Shatzen E; Rishton G; Scully S; Qi M; Harris R; Lacey D; Martin D J Pharmacol Exp Ther; 2004 Feb; 308(2):627-35. PubMed ID: 14593085 [TBL] [Abstract][Full Text] [Related]
37. Effects of calcium carbonate, sevelamer hydrochloride or pantoprazole on the pharmacokinetics of cinacalcet. Padhi D; Harris R; Sullivan JT Clin Drug Investig; 2014 Aug; 34(8):537-44. PubMed ID: 24935051 [TBL] [Abstract][Full Text] [Related]
39. Management of serum calcium reductions among patients on hemodialysis following cinacalcet initiation. Brunelli SM; Dluzniewski PJ; Cooper K; Do TP; Sibbel S; Bradbury BD Pharmacoepidemiol Drug Saf; 2015 Oct; 24(10):1058-67. PubMed ID: 26238994 [TBL] [Abstract][Full Text] [Related]
40. Relationship between parathyroid calcium-sensing receptor expression and potency of the calcimimetic, cinacalcet, in suppressing parathyroid hormone secretion in an in vivo murine model of primary hyperparathyroidism. Kawata T; Imanishi Y; Kobayashi K; Kenko T; Wada M; Ishimura E; Miki T; Nagano N; Inaba M; Arnold A; Nishizawa Y Eur J Endocrinol; 2005 Oct; 153(4):587-94. PubMed ID: 16189180 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]